RhumbLine Advisers
MIRM icon

RhumbLine Advisers’s Mirum Pharmaceuticals MIRM Stock Holding History

RhumbLine Advisers’s Portfolio MIRM Stock Details MIRM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$6.95M Buy
59,380
+7,438
+14% +$747K 0.01% 1296
2026
Q1 		$4.8M Buy
51,942
+1,168
+2% +$110K ﹤0.01% 1417
2025
Q4 		$4.01M Sell
50,774
-8,291
-14% -$595K ﹤0.01% 1517
2025
Q3 		$4.33M Sell
59,065
-5,528
-9% -$351K ﹤0.01% 1506
2025
Q2 		$3.29M Buy
64,593
+9,159
+17% +$408K ﹤0.01% 1626
2025
Q1 		$2.5M Buy
55,434
+2,321
+4% +$109K ﹤0.01% 1702
2024
Q4 		$2.2M Buy
53,113
+1,236
+2% +$51.5K ﹤0.01% 1841
2024
Q3 		$2.02M Sell
51,877
-1,039
-2% -$41.4K ﹤0.01% 1908
2024
Q2 		$1.81M Buy
52,916
+17,279
+48% +$453K ﹤0.01% 1939
2024
Q1 		$895K Sell
35,637
-187
-0.5% -$5.14K ﹤0.01% 2312
2023
Q4 		$1.06M Sell
35,824
-320
-0.9% -$9.69K ﹤0.01% 2216
2023
Q3 		$1.14M Buy
36,144
+1,867
+5% +$51.1K ﹤0.01% 2128
2023
Q2 		$887K Buy
34,277
+10,201
+42% +$271K ﹤0.01% 2359
2023
Q1 		$578K Buy
24,076
+1,261
+6% +$28.7K ﹤0.01% 2376
2022
Q4 		$445K Buy
22,815
+724
+3% +$14.3K ﹤0.01% 2522
2022
Q3 		$464K Buy
22,091
+3,747
+20% +$90.2K ﹤0.01% 2531
2022
Q2 		$357K Buy
+18,344
New +$433K ﹤0.01% 2665

Other funds holding MIRM

FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
William Blair Investment Management
William Blair Investment Management Chicago, Illinois $33.3B AUM 44.76% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

RhumbLine Advisers's MIRM Position: Q2 2026 in Review

RhumbLine Advisers increased its Mirum Pharmaceuticals (MIRM) stake by 14% in Q2 2026, buying an estimated $747K and bringing the position to 59,380 shares worth $6.95M. The position accounts for 0.01% of the portfolio, ranked #1296.

RhumbLine Advisers first reported a position in MIRM in Q2 2022 and has held it in 17 quarters since. 327 funds tracked by Wall St. Rank hold MIRM as of Q2 2026.

  • RhumbLine Advisers held 59,380 shares of Mirum Pharmaceuticals worth $6.95M as of Q2 2026.
  • RhumbLine Advisers bought 7,438 Mirum Pharmaceuticals shares in Q2 2026, an estimated $747K.
  • Mirum Pharmaceuticals made up 0.01% of RhumbLine Advisers's portfolio in Q2 2026, its #1296 holding.
  • RhumbLine Advisers first reported a position in Mirum Pharmaceuticals in Q2 2022 and has held it in 17 quarters since.
  • 327 funds tracked by Wall St. Rank held Mirum Pharmaceuticals as of Q2 2026.

Based on RhumbLine Advisers's 13F filing for Q2 2026, filed 12 Aug 2026.